Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
X, formerly known as Twitter, may collect your biometric data and job history
Japan's largest port hit with ransomware attack
AT&T Falls to 29-Year Low Amid Concerns of Cleanup Costs
Wildfire Moves Closer to Athens on High Winds and Saharan Heat
Teenager given criminal behaviour order after entering home for TikTok ‘prank’
NASA captures 'dust devil' on the surface of Mars
Woman says she was forced to change her name after Apple's latest system update
Stream Deck Goes Free – Elgato Announces Groundbreaking Changes to Mobile App